The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials.

Details

Serval ID
serval:BIB_EBFB54A04B90
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials.
Journal
Current Molecular Medicine
Author(s)
Rüegg C., Meuwly J.Y., Driscoll R., Werffeli P., Zaman K., Stupp R.
ISSN
1566-5240 (Print)
ISSN-L
1566-5240
Publication state
Published
Issued date
2003
Peer-reviewed
Oui
Volume
3
Number
8
Pages
673-691
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Abstract
Inhibition of tumor angiogenesis suppresses tumor growth and metastatic spreading in many experimental models, suggesting that anti-angiogenic drugs may be used to treat human cancer. During the past decade more than eighty molecules that showed anti-angiogenic activity in preclinical studies were tested in clinical cancer trials, but most of them failed to demonstrate any measurable anti-tumor activity and none have been approved for clinical use. Recent results stemming from trials with anti-VEGF antibodies, used alone or in combination with chemotherapy, suggest that systemic anti-angiogenic therapy may indeed have a measurable impact on cancer progression and patient survival. From the clinical studies it became nevertheless clear that the classical endpoints used in anti-cancer trials do not bring sufficient discriminative power to monitor the effects of anti-angiogenic drugs. It is therefore necessary to identify and validate molecular, cellular and functional surrogate markers of angiogenesis to monitor activity and efficacy of anti-angiogenic drugs in patients. Availability of such markers will be instrumental to re-evaluate the role of tumor angiogenesis in human cancer, to identify new molecular targets and drugs, and to improve planning, monitoring and interpretation of future studies. Future anti-angiogenesis trials integrating biological endpoints and surrogate markers or angiogenesis will require close collaboration between clinical investigators and laboratory-based researchers.
Keywords
Angiogenesis Inhibitors/therapeutic use, Animals, Antineoplastic Agents/therapeutic use, Cell Adhesion Molecules/metabolism, Clinical Trials as Topic, Drugs, Investigational/standards, Drugs, Investigational/therapeutic use, Growth Substances/therapeutic use, Humans, Neoplasms/blood supply, Neoplasms/drug therapy, Neovascularization, Pathologic/drug therapy, Neovascularization, Pathologic/metabolism, Tumor Markers, Biological/metabolism
Pubmed
Web of science
Create date
09/04/2008 15:05
Last modification date
20/08/2019 16:14
Usage data